PMID- 28464760
OWN - NLM
STAT- MEDLINE
DCOM- 20180830
LR  - 20180830
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 31
IP  - 2
DP  - 2018 Apr
TI  - Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home 
      in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
PG  - 163-166
LID - 10.1177/0897190017703507 [doi]
AB  - Pulmonary arterial hypertension (PAH) is a progressive condition that can lead to 
      right ventricular failure and death. Treprostinil is a prostacyclin analogue that 
      has proven clinical efficacy in patients with PAH. Difficulties in the 
      administration of inhaled and parenteral prostacyclins led to the development of 
      extended-release treprostinil diolamine for oral use. Limited data exist on the 
      transition to oral treprostinil. The purpose of this case series is to describe 
      the transition from subcutaneous or inhaled treprostinil to oral treprostinil in 
      the outpatient setting. With the current availability of oral prostacyclins and 
      prostacyclins analogues, most transitions to oral therapy are done in the 
      hospital setting resulting in increased cost and risk of hospital-acquired 
      infections. Four patients on background phosphodiesterase type 5 therapy with 
      baseline World Health Organization functional class (WHO FC) II PAH were 
      transitioned at home. Three of the 4 patients were safely transitioned as 
      outpatients and maintained WHO FC II status at 10 and 12 months. The fourth 
      patient had worsening right heart failure and was admitted within 2 months of the 
      transition and started back on parenteral prostacyclin therapy. The 6-minute walk 
      distance (6MWD) increased in patients transitioning from inhaled therapy and 
      decreased in the patient transitioning from subcutaneous therapy. The most common 
      adverse event was nausea.
FAU - Ackerbauer, Kimberly A
AU  - Ackerbauer KA
AD  - 1 Department of Pharmacy, Rush University Medical Center, Chicago, IL, USA.
AD  - 2 Department of Pulmonary/Critical Care Medicine, Rush University Medical Center, 
      Chicago, IL, USA.
FAU - Tandon, Rajive
AU  - Tandon R
AD  - 1 Department of Pharmacy, Rush University Medical Center, Chicago, IL, USA.
AD  - 2 Department of Pulmonary/Critical Care Medicine, Rush University Medical Center, 
      Chicago, IL, USA.
LA  - eng
PT  - Journal Article
DEP - 20170503
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 0 (Antihypertensive Agents)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - RUM6K67ESG (treprostinil)
SB  - IM
MH  - Administration, Inhalation
MH  - Administration, Oral
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Epoprostenol/administration & dosage/*analogs & derivatives
MH  - Female
MH  - Follow-Up Studies
MH  - Home Care Services/*trends
MH  - Humans
MH  - Hypertension, Pulmonary/*diagnosis/*drug therapy
MH  - Injections, Subcutaneous
MH  - Middle Aged
MH  - Retrospective Studies
OTO - NOTNLM
OT  - prostacyclin therapy
OT  - pulmonary hypertension
OT  - right heart failure
EDAT- 2017/05/04 06:00
MHDA- 2018/08/31 06:00
CRDT- 2017/05/04 06:00
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2018/08/31 06:00 [medline]
PHST- 2017/05/04 06:00 [entrez]
AID - 10.1177/0897190017703507 [doi]
PST - ppublish
SO  - J Pharm Pract. 2018 Apr;31(2):163-166. doi: 10.1177/0897190017703507. Epub 2017 
      May 3.